Vireo Growth (VREOF) Other Non-Current Assets (2020 - 2026)
Vireo Growth (VREOF) reported Other Non-Current Assets of $4.4 million for Q1 2026, up 944.53% on a YoY basis from $421244.0 in Q1 2025, and little changed sequentially from $4.4 million in Q4 2025.
Vireo Growth (VREOF) Other Non-Current Assets (2020 - 2026) Analysis & Trends
Vireo Growth (VREOF) has 7 years of Other Non-Current Assets data on file, last reported at $4.4 million in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Assets rose 944.53% year-over-year to $4.4 million; the trailing twelve-month figure through Mar 2026 stood at $4.4 million (up 944.53% YoY), and the FY2025 full-year result was $4.4 million, up 944.53% from the prior year.
- Other Non-Current Assets held at $4.4 million in Q1 2026, from $4.4 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $4.4 million in Q4 2025 to a low of $328166.0 in Q2 2025.
- A 5-year average of $1.4 million and a median of $533745.0 in 2024 frame the typical range for Other Non-Current Assets.
- Across the five-year window, Other Non-Current Assets sank 83.41% in 2023 and jumped 944.53% in 2025, its largest moves.
- Tracing VREOF's Other Non-Current Assets over 5 years: stood at $2.3 million in 2022, then slumped by 83.41% to $383645.0 in 2023, then increased by 9.8% to $421244.0 in 2024, then jumped by 944.53% to $4.4 million in 2025, then changed by 0.0% to $4.4 million in 2026.
- Business Quant data shows VREOF's Other Non-Current Assets at $4.4 million in Q1 2026, $4.4 million in Q4 2025, and $2.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 49.22 Mn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 1.79 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 351.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 491.06 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 233.20 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.11 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 73.60 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 295.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 4.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.40 Mn |
| Dec 31, 2025 | 4.40 Mn |
| Sep 30, 2025 | 2.13 Mn |
| Jun 30, 2025 | 328,166.00 |
| Mar 31, 2025 | 421,244.00 |
| Dec 31, 2024 | 421,244.00 |
| Sep 30, 2024 | 533,745.00 |
| Jun 30, 2024 | 533,745.00 |
| Mar 31, 2024 | 533,745.00 |
| Dec 31, 2023 | 383,645.00 |
| Sep 30, 2023 | 383,645.00 |
| Jun 30, 2023 | 383,645.00 |
| Mar 31, 2023 | 593,812.00 |
| Dec 31, 2022 | 2.31 Mn |
| Sep 30, 2022 | 2.18 Mn |
| Jun 30, 2022 | 2.12 Mn |
| Mar 31, 2022 | 1.99 Mn |
| Dec 31, 2021 | 1.72 Mn |
| Sep 30, 2021 | 1.34 Mn |
| Jun 30, 2021 | 1.41 Mn |